Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan · Delayed Price · Currency is TWD 77.10
-0.70 (-0.90%)
Aug 19, 2026, 11:16 AM CST
Puriblood Medical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,107 | 1,025 | 1,430 | 1,601 | 1,928 | 2,305 | |
Market Cap Growth | 3.73% | -28.36% | -10.67% | -16.97% | -16.36% | - |
Enterprise Value | 1,106 | 999 | 1,382 | 1,562 | 1,867 | 2,169 |
Last Close Price | 77.80 | 72.00 | 100.50 | 112.50 | 135.50 | 162.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 116.62 | - |
PS Ratio | 13.75 | 12.44 | 12.92 | 12.78 | 14.03 | 42.23 |
PB Ratio | 10.12 | 7.31 | 8.15 | 8.84 | 8.27 | 10.65 |
P/TBV Ratio | 10.73 | 7.71 | 8.63 | 9.49 | 8.86 | 11.11 |
P/FCF Ratio | - | - | - | 78.48 | - | - |
P/OCF Ratio | - | - | - | 60.08 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.73 | 12.13 | 12.49 | 12.47 | 13.59 | 39.73 |
EV/EBITDA Ratio | - | - | 348.23 | - | 138.76 | - |
EV/EBIT Ratio | - | - | - | - | 257.98 | - |
EV/FCF Ratio | - | - | - | 76.56 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.35 | 0.36 | 0.30 | 0.28 | 0.24 | 0.14 |
Debt / EBITDA Ratio | - | - | 9.55 | - | 3.80 | - |
Debt / FCF Ratio | - | - | - | 2.53 | - | - |
Net Debt / Equity Ratio | -0.01 | -0.07 | -0.20 | -0.36 | -0.18 | -0.47 |
Net Debt / EBITDA Ratio | 0.03 | 0.35 | -8.76 | 1.50 | -3.19 | 3.32 |
Net Debt / FCF Ratio | 0.04 | 0.34 | 1.10 | -3.23 | 1.30 | 2.17 |
Asset Turnover | 0.35 | 0.33 | 0.42 | 0.43 | 0.47 | 0.24 |
Inventory Turnover | 1.73 | 1.61 | 1.71 | 4.31 | 3.27 | 4.31 |
Quick Ratio | 1.14 | 1.56 | 2.80 | 3.16 | 3.41 | 6.41 |
Current Ratio | 1.70 | 2.12 | 3.81 | 3.88 | 5.81 | 7.99 |
Return on Equity (ROE) | -40.92% | -24.72% | -3.01% | -24.91% | 7.36% | -21.09% |
Return on Assets (ROA) | -12.97% | -8.43% | -0.65% | -10.75% | 1.54% | -9.58% |
Return on Invested Capital (ROIC) | -43.95% | -24.64% | -2.14% | -33.00% | 4.63% | -36.66% |
Return on Capital Employed (ROCE) | -33.20% | -18.70% | -1.20% | -22.30% | 2.50% | -14.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -5.04% | -3.81% | -0.38% | -3.22% | 0.86% | -1.65% |
FCF Yield | -2.95% | -2.72% | -2.22% | 1.27% | -1.71% | -2.03% |
Buyback Yield / Dilution | 0.00% | - | - | - | -22.10% | -35.52% |